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Study Short Form–12 (SF–12) and the Arizona Sexual Experi-
ence Scale (ASEX) were also administered to measure health
status and current sexual functioning, respectively. From the
survey data, a set of four preliminary estimates of ADSD preva-
lence was developed for each country. RESULTS: Use of the most
liberal estimation algorithm resulted in 32.8% of the French
patients and 52% of the UK patients being classiﬁed as suffer-
ing from ADSD; 20.4% of the French sample and 21.6% of the
UK sample were categorized as having ADSD using the most
conservative algorithm. The study results also suggested that
ADSD negatively impacts patients’ quality of life. For example,
when patients were asked about the extent to which any changes
in their sexual functioning negatively affected their self-esteem
and relationships with sexual partners, signiﬁcant differences
were found between ADSD and non-ADSD subjects using all
four prevalence estimate deﬁnitions. CONCLUSION: The
results of this study suggest that both the prevalence and impact
of ADSD in Europe are substantial. A follow-up study with an
expanded scope is currently planned to further elucidate these
issues.
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OBJECTIVES: Pharmacological treatment with alpha1-blockers
is a method used to relieve benign prostatic hyperplasia (BPH)
symptoms. Non-selective alpha1-blockers, doxazosin (DOX) and
terazosin (TER), are currently available in generic and branded
forms; the selective alpha1A-blocker, tamsulosin (TAMS), is avail-
able branded only. This study compares total health care costs
(medical and pharmacy) for patients taking TAMS compared to
those receiving DOX or TER. METHODS: A retrospective
claims analysis was performed using a large national health
plan’s database for 1999–2001. Study population consisted of
males, 40 years or older, with an initial pharmacy claim date
(index date) for TAMS, DOX or TER during the identiﬁcation
period (2000). Cohorts were formed by drug received at index
date; generic and branded products were included. Propensity
score matching was used to balance cohort baseline characteris-
tics, for TAMS versus DOX (N = 1430) and TAMS versus TER
(N = 588) in separate intent-to-treat analyses. Health care costs
between cohorts for 12 months post-index date were collected
and compared as logarithmic average costs using multivariate
regression. RESULTS: In each analysis, propensity score match-
ing was successful in eliminating baseline population differences
for 28 variables related to demographics, comorbidities, health
care visits and costs except for 2 of 7 geographic region vari-
ables. The DOX analysis found no statistically signiﬁcant dif-
ferences in total costs or BPH-medical costs for TAMS ($5936
and $361) versus DOX ($5915 and $472), although pharmacy
costs were statistically signiﬁcantly higher (p < 0.05) for TAMS
($1798) versus DOX ($1583). The TER analysis found no 
statistically signiﬁcant differences in total costs, BPH-medical
costs, or pharmacy costs for TAMS ($5946, $378, $1896) versus
TER ($6807, $791, $1683), respectively. CONCLUSIONS: This
study demonstrates the importance of considering total health
care costs instead of only pharmacy costs when comparing
alpha1-blocker treatment for BPH. Differences in total and
medical costs for TAMS offset potential pharmacy cost beneﬁts
from DOX or TER.
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OBJECTIVES: Analyze the nature of the relationship between
epoetin dose, hematocrit and mortality and determine if there
are any implications for establishing hematocrit targets.
METHODS: Hematocrit, epoetin dose, and other factors were
summarized during a 6-month period for incident ESRD patients
in the United States Renal Data System data. Mortality rates are
summarized over a 1-year follow-up. A Cox regression model
was used to evaluate the association between hematocrit, epoetin
dose, and mortality controlling for interaction between hemat-
ocrit and epoetin dose. RESULTS: Overall unadjusted mortality
rate was 251 per thousand patients. Analysis showed hematocrit
was inversely associated with epoetin dose. For the same
observed hematocrit levels, there were widely varying treatment-
related survival outcomes. In general, higher hematocrit level is
associated with lower mortality while higher epoetin dose is
associated with higher mortality. Compared to patients with an
observed study hematocrit of 33 to 36 percent and epoetin dose
in the ﬁrst dose quartile, the highest relative risk of death was
observed among patients with hematocrit values < 30 percent
and epoetin dose in the fourth dose quartile (RR = 2.14 and 95%
Ci = 1.88 to 2.42). CONCLUSIONS: Failure to control for
epoetin dosage will lead to misinterpretation of the correlation
between observed hematocrit and survival. Studies that reported
an association between hematocrit levels and survival did not
adequately control for epoetin dosage and the validity of the
inferred survival beneﬁt from increasing hematocrits is ques-
tionable. Previously published claims of a survival beneﬁt related
to higher hematocrit level should not be used to justify hemat-
ocrit targets until further studies are conducted to determine the
causal relationship.
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OBJECTIVES: In the treatment of benign prostatic hyperplasia
(BPH), patient and physician concerns regarding vasodilatory
side effects have led to the increased use of uroselective alpha-
blockade as ﬁrst-line therapy over less expensive, generic, non-
uroselective agents. This study evaluated the relative economic
impact of two currently available uroselective agents, alfuzosin
and tamsulosin. METHODS: A 1-year decision analysis was
undertaken to project the medical costs associated with treating
symptomatic BPH patients with alfuzosin vs. tamsulosin. Key
inputs included clinical data (efﬁcacy and adverse events [AEs]),
dosing, and routine medical care costs. Clinical data were
derived from a comprehensive meta-analysis published as part of
recently published BPH treatment guidelines, and resource uti-
lization information was obtained from published sources and
two nationwide physician surveys. RESULTS: Both agents had
similar efﬁcacy, however, safety proﬁles differed. Daily average
acquisition costs, after adjusting for average wholesale price for
tamsulosin ($1.99) and alfuzosin ($1.86) and increased daily
average consumption (DACON) (17% of patients required a
double dose of tamsulosin), were $1.98 vs. $1.58 per patient per
day for tamsulosin and alfuzosin, respectively. This difference
based upon price and DACON amounted to $146.00 per patient
per year (PPPY) (tamsulosin = $722.70, alfuzosin = $576.70).
Costs associated with tamsulosin-related AEs were estimated to
be $4.59 PPPY, whereas, alfuzosin-related AEs were $2.25 PPPY
($2.34 PPPY difference). Therefore, in considering the price and
DACON differential ($146.00) together with the differential in
costs of treating AEs ($2.34), alfuzosin saved $148.34 PPPY, 
a 20% difference. CONCLUSIONS: Alfuzosin provides cost
savings over tamsulosin in the treatment of patients with symp-
tomatic BPH. Savings are realized primarily on the basis of total
drug acquisition costs, followed by lower costs associated with
treating side effects of therapy. Alfuzosin is a less expensive alter-
native to tamsulosin as a ﬁrst-line clinically uroselective drug
therapy in the management of men with BPH.
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OBJECTIVES: This analysis addresses the cost-effectiveness of
the extended release formulation of oxybutynin (Ditropan XL)
relative to long-acting tolterodine (Detrol LA) for the treatment
of overactive bladder in the US. METHODS: A previously vali-
dated state-transition model was used to compare the health eco-
nomic outcomes over the course of one year using efﬁcacy data
from OPERA, a 3-month randomized, double-blind trial com-
paring Ditropan XL 10mg once daily to Detrol LA 4mg once
daily, together with data from the literature to project outcomes
beyond trial time. Five states were deﬁned based on the severity
of symptoms (number of incontinent episodes per week). 
Severity-speciﬁc costs (in 2003 US dollars) of pharmaceuticals,
doctor visits, and pad or protection usage for incontinence in the
US were used. RESULTS: Ditropan XL is expected to lead to
superior outcomes and lower overall costs compared to Detrol
LA. After one year, 4.6 more patients per 100 treated attain com-
plete continence and an additional 2.4 more will have fewer than
7 incontinent episodes per week. Patients on Ditropan XL have
almost 11 additional incontinence free days over the course of
the year. Costs are expected to be an average of $43 lower per
patient per year. Ditropan XL maintains its advantage over wide
ranges of inputs, and outcomes are similar if analyses are limited
to only 3 months, the duration of the OPERA trial. CONCLU-
SIONS: These analyses suggest that Ditropan XL provides better
health outcomes and lower costs compared to Detrol LA over a
1-year period.
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OBJECTIVES: The age related prevalence of Overactive Bladder
in developed economies is estimated at 17% and is comparable
with common diseases including depression, osteoporosis, and
COPD. The burden of OAB is likely to grow in the future. The
